

# NEUAC- clindamycin phosphate and benzoyl peroxide gel

## Medimetriks Pharmaceuticals

-----

### HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use Neucac<sup>®</sup> (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/5% safely and effectively. See full prescribing information for Neucac<sup>®</sup> (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/5%.

Neucac<sup>®</sup> (CLINDAMYCIN PHOSPHATE and BENZOYL PEROXIDE) gel, for topical use.

Initial U.S. Approval: 2000

### INDICATIONS AND USAGE

Neucac<sup>®</sup> (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/5% is a combination of clindamycin phosphate (a lincosamide antibacterial) and benzoyl peroxide indicated for the topical treatment of inflammatory acne vulgaris. (1.1)

Limitation of Use:

Neucac<sup>®</sup> (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/5% has not been demonstrated to have any additional benefit when compared with benzoyl peroxide alone in the same vehicle when used for the treatment of non-inflammatory acne. (1.2)

### DOSAGE AND ADMINISTRATION

- Apply a thin layer of Neucac<sup>®</sup> (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/5% to the face once daily, in the evening. (2)
- Not for oral, ophthalmic, or intravaginal use. (2)

### DOSAGE FORMS AND STRENGTHS

Gel, 1.2%/5%: Each gram of Neucac<sup>®</sup> (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/5% contains 12 mg clindamycin phosphate (equivalent to 10 mg of clindamycin) and 50 mg benzoyl peroxide. (3)

### CONTRAINDICATIONS

Neucac<sup>®</sup> (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/5% is contraindicated in:

- Patients who have demonstrated hypersensitivity (e.g., anaphylaxis) to clindamycin, benzoyl peroxide, any components of the formulation, or lincomycin. (4)
- Patients with a history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis (including pseudomembranous colitis). (4)

### WARNINGS AND PRECAUTIONS

- Colitis: Clindamycin can cause severe colitis, which may result in death. Diarrhea, bloody diarrhea, and colitis (including pseudomembranous colitis) have been reported with the use of clindamycin. Neucac<sup>®</sup> (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/5% should be discontinued if significant diarrhea occurs. (5.1)
- Ultraviolet light and environmental exposure (including use of tanning beds or sun lamps): Minimize sun exposure following drug application. (5.2)

### ADVERSE REACTIONS

- The most common local adverse reactions (≥5%) are erythema, peeling, dryness, and burning. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Medimetriks Pharmaceuticals, Inc. at 973-882-7512 or the FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).

### DRUG INTERACTIONS

- Neucac<sup>®</sup> (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/5% should not be used in combination with erythromycin-containing products because of its clindamycin component. (7.1)

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

Revised: 11/2015

---

**FULL PRESCRIBING INFORMATION: CONTENTS\***

## **1 INDICATIONS AND USAGE**

- 1.1 Indication
- 1.2 Limitations of Use

## **2 DOSAGE AND ADMINISTRATION**

## **3 DOSAGE FORMS AND STRENGTHS**

## **4 CONTRAINDICATIONS**

- 4.1 Hypersensitivity
- 4.2 Colitis/Enteritis

## **5 WARNINGS AND PRECAUTIONS**

- 5.1 Colitis
- 5.2 Ultraviolet Light and Environmental Exposure

## **6 ADVERSE REACTIONS**

- 6.1 Clinical Trials Experience
- 6.2 Postmarketing Experience

## **7 DRUG INTERACTIONS**

- 7.1 Erythromycin
- 7.2 Concomitant Topical Medications
- 7.3 Neuromuscular Blocking Agents
- 7.4 Topical Sulfone Products

## **8 USE IN SPECIFIC POPULATIONS**

- 8.1 Pregnancy
- 8.3 Nursing Mothers
- 8.4 Pediatric Use
- 8.5 Geriatric Use

## **11 DESCRIPTION**

## **12 CLINICAL PHARMACOLOGY**

- 12.1 Mechanism of Action
- 12.3 Pharmacokinetics
- 12.4 Microbiology

## **13 NONCLINICAL TOXICOLOGY**

- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

## **14 CLINICAL STUDIES**

## **16 HOW SUPPLIED/STORAGE AND HANDLING**

- 16.1 How Supplied
- 16.2 Storage and Handling
- 16.3 Dispensing Instructions for the Pharmacist

## **17 PATIENT COUNSELING INFORMATION**

\* Sections or subsections omitted from the full prescribing information are not listed.

---

## **FULL PRESCRIBING INFORMATION**

### **1 INDICATIONS AND USAGE**

#### **1.1 Indication**

Neuac<sup>®</sup> (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/5% is indicated for the topical treatment of inflammatory acne vulgaris in patients 12 years and older.

#### **1.2 Limitations of Use**

Neuac<sup>®</sup> (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/5% has not been demonstrated to have

any additional benefit when compared with benzoyl peroxide alone in the same vehicle when used for the treatment of non-inflammatory acne.

## **2 DOSAGE AND ADMINISTRATION**

Apply a thin layer of Neuac<sup>®</sup> (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/5% to the face once daily, in the evening or as directed by the physician. The skin should be gently washed, rinsed with warm water, and patted dry before applying Neucac<sup>®</sup> (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/5%. Avoid the eyes, mouth, lips, mucous membranes, or areas of broken skin.

Neuac<sup>®</sup> (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/5% is not for oral, ophthalmic, or intravaginal use.

## **3 DOSAGE FORMS AND STRENGTHS**

Gel, 1.2%/5%

Neuac<sup>®</sup> (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/5% is a white, opaque gel. Each gram of Neucac<sup>®</sup> (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/5% contains 12 mg clindamycin phosphate (equivalent to 10 mg of clindamycin) and 50 mg benzoyl peroxide.

## **4 CONTRAINDICATIONS**

### **4.1 Hypersensitivity**

Neuac<sup>®</sup> (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/5% is contraindicated in those individuals who have shown hypersensitivity to clindamycin, benzoyl peroxide, any components of the formulation, or lincomycin. Anaphylaxis, as well as allergic reactions leading to hospitalization, has been reported in postmarketing use with clindamycin phosphate and benzoyl peroxide gel, 1.2%/5% [see *Adverse Reactions (6.2)*].

### **4.2 Colitis/Enteritis**

Neuac<sup>®</sup> (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/5% is contraindicated in those individuals with a history of regional enteritis, ulcerative colitis, pseudomembranous colitis, or antibiotic-associated colitis [see *Warnings and Precautions (5.1)*].

## **5 WARNINGS AND PRECAUTIONS**

### **5.1 Colitis**

Systemic absorption of clindamycin has been demonstrated following topical use of clindamycin. Diarrhea, bloody diarrhea, and colitis (including pseudomembranous colitis) have been reported with the use of topical and systemic clindamycin. If significant diarrhea occurs, Neuac<sup>®</sup> (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/5% should be discontinued.

Severe colitis has occurred following oral and parenteral administration of clindamycin with an onset of up to several weeks following cessation of therapy. Antiperistaltic agents such as opiates and diphenoxylate with atropine may prolong and/or worsen severe colitis. Severe colitis may result in death.

Studies indicate a toxin(s) produced by Clostridia is one primary cause of antibiotic-associated colitis. The colitis is usually characterized by severe persistent diarrhea and severe abdominal cramps and may be associated with the passage of blood and mucus. Stool cultures for *Clostridium difficile* and stool assay for *C. difficile* toxin may be helpful diagnostically.

## 5.2 Ultraviolet Light and Environmental Exposure

Benzoyl peroxide, a component of Neucac<sup>®</sup> (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/5%, may cause increased sensitivity to sunlight. Minimize sun exposure (including use of tanning beds or sun lamps) following drug application. [See *Nonclinical Toxicology (13.1)*] Patients who may be required to have considerable sun exposure due to occupation and those with inherent sensitivity to the sun should exercise particular caution.

## 6 ADVERSE REACTIONS

The following adverse reaction is described in more detail in the *Warnings and Precautions* section of the label:

- Colitis [see *Warnings and Precautions (5.1)*].

### 6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.

During clinical trials, 397 subjects used clindamycin phosphate and benzoyl peroxide gel, 1.2%/5% once daily for 11 weeks for the treatment of moderate to moderately severe facial acne vulgaris. All subjects were graded for facial local skin reactions (erythema, peeling, burning, and dryness) on the following scale: 0 = absent, 1 = mild, 2 = moderate, and 3 = severe. The percentage of subjects that had symptoms present before treatment (at baseline) and during treatment is presented in Table 1.

**Table 1. Local Skin Reactions With Use Of Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/5% Combined Results From Five Trials (n=397)**

Symptom	% of Subjects Using Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/5% with Symptom Present					
	Before Treatment (Baseline)			During Treatment		
	Mild	Moderate	Severe	Mild	Moderate	Severe
Erythema	28%	3%	0	26%	5%	0
Peeling	6%	<1%	0	17%	2%	0
Burning	3%	<1%	0	5%	<1%	0
Dryness	6%	<1%	0	15%	1%	0

(Percentages derived by number of subjects receiving clindamycin phosphate and benzoyl peroxide gel, 1.2%/5% with symptom score/number of enrolled subjects receiving clindamycin phosphate and benzoyl peroxide gel, 1.2%/5%).

### 6.2 Postmarketing Experience

The following adverse reactions have been identified during post approval use of clindamycin phosphate and benzoyl peroxide gel, 1.2%/5%. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Anaphylaxis, as well as allergic reactions leading to hospitalization, has been reported in postmarketing use with clindamycin phosphate and benzoyl peroxide gel, 1.2%/5%.

Urticaria, application site reactions, including discoloration have been reported.

## 7 DRUG INTERACTIONS

## **7.1 Erythromycin**

Avoid using Neucac<sup>®</sup> (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/5% in combination with erythromycin-containing products due to its clindamycin component. In vitro studies have shown antagonism between erythromycin and clindamycin. The clinical significance of this in vitro antagonism is not known.

## **7.2 Concomitant Topical Medications**

Concomitant topical acne therapies should be used with caution since a possible cumulative irritancy effect may occur, especially with the use of peeling, desquamating, or abrasive agents. If irritancy or dermatitis occurs, reduce frequency of application or temporarily interrupt treatment and resume once the irritation subsides. Treatment should be discontinued if the irritation persists.

## **7.3 Neuromuscular Blocking Agents**

Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Neucac<sup>®</sup> (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/5% should be used with caution in patients receiving such agents.

## **7.4 Topical Sulfone Products**

Use of topical benzoyl-peroxide-containing preparations with topical sulfone products may cause skin and facial hair to temporarily change color (yellow/orange).

# **8 USE IN SPECIFIC POPULATIONS**

## **8.1 Pregnancy**

Pregnancy Category C.

There are no adequate and well-controlled studies in pregnant women treated with Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/5%. Neucac<sup>®</sup> (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/5% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Developmental toxicity studies performed in rats and mice using oral doses of clindamycin up to 600 mg per kg per day (240 and 120 times the amount of clindamycin in the highest recommended adult human dose based on mg per m<sup>2</sup>, respectively) or subcutaneous doses of clindamycin up to 250 mg per kg per day (100 and 50 times the amount of clindamycin in the highest recommended adult human dose based on mg per m<sup>2</sup>, respectively) revealed no evidence of teratogenicity.

## **8.3 Nursing Mothers**

It is not known whether Neucac<sup>®</sup> (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/5% is excreted into human milk after topical application.

However, orally and parenterally administered clindamycin has been reported to appear in breast milk. Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Because many drugs are excreted in human milk, caution should be exercised when Neucac<sup>®</sup> (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/5% is administered to a nursing woman.

## **8.4 Pediatric Use**

Safety and effectiveness of clindamycin phosphate and benzoyl peroxide gel, 1.2%/5% in pediatric patients below the age of 12 have not been established.

## 8.5 Geriatric Use


Clinical studies of clindamycin phosphate and benzoyl peroxide gel, 1.2%/5% did not include sufficient numbers of subjects ages 65 and over to determine whether they respond differently from younger subjects.

## 11 DESCRIPTION

Neuac<sup>®</sup> (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/5% is a fixed combination product with two active ingredients in a white, opaque, aqueous gel formulation.


Clindamycin phosphate is a water soluble ester of the semi-synthetic antibiotic produced by a 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the parent antibiotic lincomycin.

Clindamycin phosphate is  $C_{18}H_{34}ClN_2O_8PS$ . The structural formula for clindamycin phosphate is represented below:



Clindamycin phosphate has a molecular weight of 504.97 and its chemical name is methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-*trans*-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-*threo*-α-D-*galacto*-octopyranoside 2-(dihydrogen phosphate).

Benzoyl peroxide is  $C_{14}H_{10}O_4$ . It has the following structural formula:



Benzoyl peroxide has a molecular weight of 242.23.

Each gram of Neucac<sup>®</sup> (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/5% contains 10 mg (1%) clindamycin, as clindamycin phosphate, and 50 mg (5%) benzoyl peroxide in a base consisting of carbomer homopolymer (type B), hydrochloric acid, methylparaben, dimethicone, propylparaben, purified water and sodium hydroxide.

## 12 CLINICAL PHARMACOLOGY

### 12.1 Mechanism of Action

Clindamycin: Clindamycin is a lincosamide antibacterial [see *Clinical Pharmacology* (12.4)].

Benzoyl Peroxide: Benzoyl peroxide is an oxidizing agent with bacteriocidal and keratolytic effects, but the precise mechanism of action is unknown.

### 12.3 Pharmacokinetics

A comparative trial of the pharmacokinetics of clindamycin phosphate and benzoyl peroxide gel, 1.2%/5% and 1% clindamycin solution alone in 78 subjects indicated that mean plasma clindamycin levels during the 4-week dosing period were less than 0.5 ng/mL for both treatment groups.

Benzoyl peroxide has been shown to be absorbed by the skin where it is converted to benzoic acid. Less than 2% of the dose enters systemic circulation as benzoic acid.

### 12.4 Microbiology

Clindamycin binds to the 50S ribosomal subunits of susceptible bacteria and prevents elongation of peptide chains by interfering with peptidyl transfer, thereby suppressing protein synthesis.

In Vivo Activity: No microbiology studies were conducted in the clinical trials with this product.

In Vitro Activity: The clindamycin and benzoyl peroxide components individually have been shown to have in vitro activity against *Propionibacterium acnes*, an organism which has been associated with acne vulgaris; however, the clinical significance of this in vitro activity is not known.

Drug Resistance: There are reports of an increase of *P. acnes* resistance to clindamycin in the treatment of acne. In patients with *P. acnes* resistant to clindamycin, the clindamycin component may provide no additional benefit beyond benzoyl peroxide alone.

## 13 NONCLINICAL TOXICOLOGY

### 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Benzoyl peroxide has been shown to be a tumor promoter and progression agent in a number of animal studies. Benzoyl peroxide in acetone at doses of 5 and 10 mg administered twice per week induced squamous cell skin tumors in transgenic TgAC mice in a study using 20 weeks of topical treatment. The clinical significance of this is unknown.

In a 2-year dermal carcinogenicity study in mice, treatment with clindamycin phosphate and benzoyl peroxide gel, 1.2%/5% at doses up to 8,000 mg per kg per day (16 times the highest recommended adult human dose of 2.5 g clindamycin phosphate and benzoyl peroxide gel, 1.2%/5%, based on mg per m<sup>2</sup>) did not cause an increase in skin tumors. However, topical treatment with another formulation containing 1% clindamycin and 5% benzoyl peroxide at doses of 100, 500, or 2,000 mg per kg per day caused a dose-dependent increase in the incidence of keratoacanthoma at the treated skin site of male rats in a 2-year dermal carcinogenicity study in rats.

In a 52-week photocarcinogenicity study in hairless mice (40 weeks of treatment followed by 12 weeks of observation), the median time to onset of skin tumor formation decreased and the number of tumors

per mouse increased relative to controls following chronic concurrent topical treatment with clindamycin phosphate and benzoyl peroxide gel, 1.2%/5% and exposure to ultraviolet radiation.

Genotoxicity studies were not conducted with clindamycin phosphate and benzoyl peroxide gel, 1.2%/5%. Clindamycin phosphate was not genotoxic in *Salmonella typhimurium* or in a rat micronucleus test. Benzoyl peroxide has been found to cause DNA strand breaks in a variety of mammalian cell types, to be mutagenic in *Salmonella typhimurium* tests by some but not all investigators, and to cause sister chromatid exchanges in Chinese hamster ovary cells.

Studies have not been performed with clindamycin phosphate and benzoyl peroxide gel, 1.2%/5% or benzoyl peroxide to evaluate the effect on fertility. Fertility studies in rats treated orally with up to 300 mg per kg per day of clindamycin (approximately 120 times the amount of clindamycin in the highest recommended adult human dose of 2.5 g clindamycin phosphate and benzoyl peroxide gel, 1.2%/5%, based on mg per m<sup>2</sup>) revealed no effects on fertility or mating ability.

## 14 CLINICAL STUDIES

In five randomized, double-blind clinical trials of 1,319 subjects, 397 used clindamycin phosphate and benzoyl peroxide gel, 1.2%/5%, 396 used benzoyl peroxide, 349 used clindamycin, and 177 used vehicle. Subjects were instructed to wash the face, wait 10 to 20 minutes, and then apply medication to the entire face, once daily in the evening before retiring. Clindamycin phosphate and benzoyl peroxide gel, 1.2%/5% applied once daily for 11 weeks was significantly more effective than vehicle, benzoyl peroxide, and clindamycin in the treatment of inflammatory lesions of moderate to moderately severe facial acne vulgaris in three of the five trials (Trials 1, 2, and 5). Subjects were evaluated and acne lesions counted at each clinical visit at Weeks 2, 5, 8, 11.

The primary efficacy measures were the lesion counts and the investigator's global assessment evaluated at Week 11. Percent reductions in inflammatory lesion counts after treatment for 11 weeks in these 5 trials are shown in Table 2.

**Table 2. Mean Percent Reduction In Inflammatory Lesion Counts**

<b>Treatment</b>	<b>Trial 1 (n = 120)</b>	<b>Trial 2 (n = 273)</b>	<b>Trial 3 (n = 280)</b>	<b>Trial 4 (n = 288)</b>	<b>Trial 5 (n = 358)</b>
Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/5%	65%	56%	42%	57%	52%
Benzoyl Peroxide	36%	37%	32%	57%	41%
Clindamycin	34%	30%	38%	49%	33%
Vehicle	19%	-0.4%	29%	--	29%

The group treated with clindamycin phosphate and benzoyl peroxide gel, 1.2%/5% showed greater overall improvement in the investigator's global assessment than the benzoyl peroxide, clindamycin, and vehicle groups in three of the five trials (Trials 1, 2, and 5).

Clinical trials have not adequately demonstrated the effectiveness of clindamycin phosphate and benzoyl peroxide gel, 1.2%/5% versus benzoyl peroxide alone in the treatment of non-inflammatory lesions of acne.

## 16 HOW SUPPLIED/STORAGE AND HANDLING

### 16.1 How Supplied

Neuac<sup>®</sup> (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/5% is a white, opaque gel. It is supplied as follows:

- 45 gram tube      NDC 43538-176-45



## 16.2 Storage and Handling

### Pharmacist:

- Prior to Dispensing: Store in a cold place, preferably in a refrigerator, between 2°C and 8°C (36°F and 46°F). Do not freeze.

## 16.3 Dispensing Instructions for the Pharmacist

- Dispense Neucac<sup>®</sup> (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/5% with a 60-day expiration date.
- Specify "Store at room temperature up to 25°C (77°F). Do not freeze."
- Keep tube tightly closed.
- Keep out of the reach of small children.

## 17 PATIENT COUNSELING INFORMATION

See FDA-approved patient labeling (Patient Information).

- Patients who develop allergic reactions such as severe swelling or shortness of breath should discontinue use and contact their physician immediately.
- Neucac<sup>®</sup> (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/5% may cause irritation such as erythema, scaling, itching, or burning, especially when used in combination with other topical acne therapies.
- Excessive or prolonged exposure to sunlight should be limited. To minimize exposure to sunlight, a hat or other clothing should be worn. Sunscreen may also be used.
- Neucac<sup>®</sup> (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/5% may bleach hair or colored fabric.
- Neucac<sup>®</sup> (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/5% may cause skin and facial hair to temporarily change color (yellow/orange) when used with topical sulfone products.

Manufactured for Medimetriks Pharmaceuticals, Inc.  
383 Route 46 West, Fairfield, NJ 07004-2402 USA

Manufactured By Perrigo, Yeruham, Israel • Made in Israel

Distributed By Perrigo, Allegan, MI 49010

Rev 11/2015  
IP037-R1  
5M400 EK J1

## PATIENT INFORMATION

### Neucac<sup>®</sup> (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/5%

Important: For use on the skin only (topical use). Do not get Neucac<sup>®</sup> (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/5% in your mouth, eyes, vagina, or on your lips.

Read this Patient Information before you start using Neucac<sup>®</sup> (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/5% and each time you get a refill. There may be new information. This information does not take the place of talking with your healthcare provider about your medical condition or your treatment.

### What is Neucac<sup>®</sup> (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/5%?

Neucac<sup>®</sup> Gel is a prescription medicine used on the skin (topical) to treat inflamed acne in people 12 years and older.

## **Who should not use Neucac<sup>®</sup> (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/5%?**

### **Do not use Neucac<sup>®</sup> Gel if you have:**

- had an allergic reaction to clindamycin, lincomycin, benzoyl peroxide, or any of the ingredients in Neucac<sup>®</sup> (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/5%. See the end of this leaflet for a complete list of ingredients in Neucac<sup>®</sup> Gel.
- Crohn's disease or ulcerative colitis.
- had inflammation of the colon (colitis) with past antibiotic use.

## **What should I tell my healthcare provider before using Neucac<sup>®</sup> (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/5%?**

### **Before using Neucac<sup>®</sup> Gel, tell your healthcare provider about all of your medical conditions, including if you:**

- plan to have surgery with general anesthesia.
- are sensitive to sunlight.
- are pregnant or plan to become pregnant. It is not known if Neucac<sup>®</sup> Gel, will harm your unborn baby.
- are breastfeeding or plan to breastfeed. It is not known if Neucac<sup>®</sup> Gel passes into your breast milk. One of the medicines in Neucac<sup>®</sup> Gel is clindamycin. Clindamycin when taken by mouth or by injection has been reported to appear in breast milk. You and your healthcare provider should decide if you will use Neucac<sup>®</sup> Gel while breastfeeding.

**Tell your healthcare provider about all the medicines you take**, including prescription or over-the-counter medicines, vitamins, herbal supplements, and skin products you use. Using other topical acne products may increase the irritation of your skin when used with Neucac<sup>®</sup> (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/5%.

- Especially tell your healthcare provider if you take a medicine that contains erythromycin. Neucac<sup>®</sup> Gel should not be used with products that contain erythromycin.
- Neucac<sup>®</sup> Gel may cause skin and facial hair to temporarily change color (yellow or orange) when used with topical products that contain sulfones.

## **How should I use Neucac<sup>®</sup> (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/5%?**

- Use Neucac<sup>®</sup> Gel exactly as your healthcare provider tells you to use it.
- Before you apply Neucac<sup>®</sup> Gel, wash your face gently with a mild soap, rinse with warm water, and pat the skin dry.
- Apply a thin layer of Neucac<sup>®</sup> Gel to your face 1 time a day, in the evening or as directed by your healthcare provider. Wash your hands with soap and water after applying Neucac<sup>®</sup> Gel.
- Do not get Neucac<sup>®</sup> Gel in your mouth, eyes, nose, vagina, or on your lips. Do not get Neucac<sup>®</sup> Gel on cuts or open wounds.

## **What should I avoid while using Neucac<sup>®</sup> (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/5%?**

- Limit your time in sunlight. Avoid using tanning beds or sun lamps. If you have to be in sunlight, wear a wide-brimmed hat or other protective clothing. Sunscreen may also be used.
- Talk to your healthcare provider if you spend a lot of time in the sun.
- Neucac<sup>®</sup> Gel may bleach hair or colored fabric.

## **What are the possible side effects with Neucac<sup>®</sup> (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/5%?**

### **Neucac<sup>®</sup> Gel may cause serious side effects, including:**

- **Inflammation of the colon (colitis).** Stop using Neucac<sup>®</sup> Gel and call your healthcare provider right away if you have severe watery diarrhea, or bloody diarrhea.
- **Allergic reactions.** Stop using Neucac<sup>®</sup> Gel and call your healthcare provider or get help right away

if you have any of the following symptoms:

- severe itching
- swelling of your face, eyes, lips, tongue, or throat
- trouble breathing

**The most common side effects with Neuac<sup>®</sup> (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/5%** are skin reactions and may include redness, peeling, dryness, and burning.

These are not all the possible side effects with Neuac<sup>®</sup> Gel.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

**How should I store Neuac<sup>®</sup> (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/5%?**

- Store Neuac<sup>®</sup> Gel at room temperature up to 25°C (77°F). Do not freeze Neuac<sup>®</sup> Gel.
- The expiration date of Neuac<sup>®</sup> Gel is 60 days from the date when you fill your prescription.
- Safely throw away expired Neuac<sup>®</sup> Gel.
- Keep the tube tightly closed.

**Keep Neuac<sup>®</sup> Gel and all medicines out of the reach of children.**

**General information about Neuac<sup>®</sup> (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/5%**

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use Neuac<sup>®</sup> Gel for a condition for which it was not prescribed. Do not give Neuac<sup>®</sup> Gel to other people, even if they have the same symptoms you have. It may harm them.

If you would like more information, talk with your healthcare provider. You can also ask your pharmacist or healthcare provider for information about Neuac<sup>®</sup> Gel that is written for health professionals.

**What are the ingredients in Neuac<sup>®</sup> (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/5%?**

**Active Ingredients:** clindamycin phosphate 1.2% and benzoyl peroxide 5%

**Inactive ingredients:** carbomer homopolymer (type B), hydrochloric acid, methylparaben, dimethicone, propylparaben, purified water and sodium hydroxide.

This Patient Information has been approved by the U.S. Food and Drug Administration.

Manufactured For Medimetriks Pharmaceuticals, Inc.  
383 Route 46 West, Fairfield, NJ 07004-2402 USA

Manufactured By Perrigo, Yeruham, Israel • Made in Israel

Distributed By Perrigo, Allegan, MI 49010

Rev 11/2015  
IP037-R1  
5M400 EK J1

**PRINCIPAL DISPLAY PANEL - 45 g Tube Carton**

NDC 43538-176-45


R<sub>x</sub> Only  
**Neuac<sup>®</sup>**

(clindamycin phosphate and  
benzoyl peroxide) Gel, 1.2%/5%

**For External Use Only**

45 g

**MEDIMETRIKS  
PHARMACEUTICALS, INC.**



**NEUAC**

clindamycin phosphate and benzoyl peroxide gel

**Product Information**

<b>Product Type</b>	HUMAN PRESCRIPTION DRUG	<b>Item Code (Source)</b>	NDC:43538-176
<b>Route of Administration</b>	TOPICAL		

**Active Ingredient/Active Moiety**

Ingredient Name	Basis of Strength	Strength
<b>clindamycin phosphate</b> (UNII: EH6D7113I8) (clindamycin - UNII:3U02EL437C)	clindamycin	10 mg in 1 g
<b>benzoyl peroxide</b> (UNII: W9WZN9A0GM) (benzoyl peroxide - UNII:W9WZN9A0GM)	benzoyl peroxide	50 mg in 1 g

**Inactive Ingredients**

Ingredient Name	Strength
<b>hydrochloric acid</b> (UNII: QTT17582CB)	
<b>methylparaben</b> (UNII: A2I8C7HI9T)	
<b>dimethicone</b> (UNII: 92RU3N3Y1O)	

<b>propylparaben</b> (UNII: Z8IX2SC1OH)	
<b>water</b> (UNII: 059QF0KO0R)	
<b>sodium hydroxide</b> (UNII: 55X04QC32I)	

### Product Characteristics

<b>Color</b>	WHITE	<b>Score</b>	
<b>Shape</b>		<b>Size</b>	
<b>Flavor</b>		<b>Imprint Code</b>	
<b>Contains</b>			

### Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:43538-176-45	1 in 1 CARTON	06/15/2014	
1		45 g in 1 TUBE; Type 0: Not a Combination Product		

### Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA090979	06/15/2014	

**Labeler** - Medimetriks Pharmaceuticals (019903816)

### Establishment

Name	Address	ID/FEI	Business Operations
Perrigo Israel		600093611	MANUFACTURE(43538-176)

Revised: 11/2015

Medimetriks Pharmaceuticals